Daniel Benamran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel Benamran has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Sasia
Department of Surgical Sciences, Urology Unit, Molinette Hospital, University of Torino, Italy
1 shared publication - Alexandre Fourcade
Department of Urology, Centre hospitalier universitaire de Brest, France
1 shared publication - Arnaud Mejean
Department of Urology, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris-Cité, Hôpital Européen Georges Pompidou (HEGP), 75015 Paris, France
1 shared publication - Arthur Peyrottes
Urology Department, Saint-Louis University Hospital, AP-HP, Paris, France
1 shared publication - Charles Dariane
Hôpital européen Georges-Pompidou, Paris, France
1 shared publication - Claire Siebert
Department of Urology, Centre hospitalier universitaire de Brest, France
1 shared publication
Latest Publications
- Open Access
- 29 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (8) , 61-69
ISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes
- 29 May 2026
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (8) , 61-69
Open AccessISUP 2 prostate cancer with suspicion of extraprostatic extension on MRI: Prostatectomy results and oncologic outcomes
- Open Access
- 27 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1269
Rational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell Carcinoma
Background/Objectives: Despite recent therapeutic advances, the clinical management of renal cell carcinoma (RCC) remains suboptimal. Current treatments are hindered by limited efficacy, the emergence of acquired drug resistance, suboptimal tolerability, and a lack of tumor-specific targeting. While development of novel agents remains an important avenue, it is often constrained by high costs, long development time, and low success rates. As an alternative approach, drug combinations of approved agents offer a promising strategy. Methods: Using our proprietary drug combination methodology, we identified multidrug combinations in RCC cells representing the clear cell (786O) and sarcomatoid chromophobe (UOK276) histological subtypes of RCC. Results: From an initial panel of 10 drugs, either approved or undergoing clinical trial, the optimized drug combinations (ODCs) contained crizotinib, telaglenastat, U-104, and vismodegib at clinical and subtherapeutic doses. The ODCs were non-toxic in advanced hepatic, renal, and cardiac cellular models. Importantly, their anti-tumor activity, already notable in normoxic (21% O2) conditions (approx. 50%) was markedly enhanced in tumor-relevant hypoxia (1.5% O2), reaching up to 77% in 2D and 62% in 3D spheroid 786O models. Moreover, chronic exposure of 786O and UOK276 cells led to durable responses, suggesting a prolonged effect in responders. Conclusions: Our findings demonstrate the potential of optimized, non-toxic drug combinations as a highly selective and effective strategy for accelerating the development of precision RCC treatment.
- 27 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1269
Open AccessRational Design of Non-Toxic Multidrug Combinations Demonstrates Durable and Hypoxia-Enhanced Efficacy Against Renal Cell Carcinoma
Background/Objectives: Despite recent therapeutic advances, the clinical management of renal cell carcinoma (RCC) remains suboptimal. Current treatments are hindered by limited efficacy, the emergence of acquired drug resistance, suboptimal tolerability, and a lack of tumor-specific targeting. While development of novel agents remains an important avenue, it is often constrained by high costs, long development time, and low success rates. As an alternative approach, drug combinations of approved agents offer a promising strategy. Methods: Using our proprietary drug combination methodology, we identified multidrug combinations in RCC cells representing the clear cell (786O) and sarcomatoid chromophobe (UOK276) histological subtypes of RCC. Results: From an initial panel of 10 drugs, either approved or undergoing clinical trial, the optimized drug combinations (ODCs) contained crizotinib, telaglenastat, U-104, and vismodegib at clinical and subtherapeutic doses. The ODCs were non-toxic in advanced hepatic, renal, and cardiac cellular models. Importantly, their anti-tumor activity, already notable in normoxic (21% O2) conditions (approx. 50%) was markedly enhanced in tumor-relevant hypoxia (1.5% O2), reaching up to 77% in 2D and 62% in 3D spheroid 786O models. Moreover, chronic exposure of 786O and UOK276 cells led to durable responses, suggesting a prolonged effect in responders. Conclusions: Our findings demonstrate the potential of optimized, non-toxic drug combinations as a highly selective and effective strategy for accelerating the development of precision RCC treatment.